TOPICS

Canerpaturev was listed in WHO recommended International Nonproprietary Names as HF10' generic name. [New!]



Expanded Phase I Study of HF10 in Pancreatic Cancer Patients[New!]


Takara Bio is currently conducting a phase I clinical trial of Oncolytic Virus HF10(Development Code: TBI-1401(HF10) targeting pancreatic cancer in Japan, and amended its protocol to expand the trial. (Extended stage; 30 patients total)

In Japan, the combination of Gemcitabine and Nab-paclitaxel is currently the first-line treatment and TS-1® is accepted as the second- or third-line treatment for advanced pancreatic cancer. In this expansion phase, we will assess the safety and efficacy of HF10 in combination with these standard therapies.

Study Title: Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Japanese Patients With Stage III or IV Unresectable Pancreatic Cancer (Clinicaltrials.gov. identifier: NCT03252808)


Takara Bio entered into an agreement for co-development/exclusive sales of NY-ESO-1 siTCR™ and CD19 CAR gene therapy with Otsuka


Click here for the detail > News Release (2018/04/09)


Announcement on product designation of NY-ESO-1 siTCR gene therapy product for synovial sarcoma under "SAKIGAKE Designation System" by the Ministry of Health, Labour and Welfare


Click here for the detail > News Release (2018/04/06)


First patient enrolled into phase I/II clinical trial of NY-ESO-1 siTCR™ gene therapy against synovial sarcoma in Japan


Click here for the detail > News Release (2018/01/19)


Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab


Click here for the detail > News Release (2017/12/21)


First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan


Click here for the detail > News Release (2017/09/27)


Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan


Click here for the detail > News Release (2017/06/01)


First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan


Click here for the detail > News Release (2017/05/29)


Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology


Click here for the detail > News Release (2017/05/23)


return to top